Vascular Targeted Photodynamic Therapy for Prostate Tumors



Urologic surgeon Jonathan Coleman discusses vascular targeted photodynamic (VTP) therapy to destroy prostate tumors and the blood vessels that support them by delivering the intravenous drug TOOKAD®. The drug is activated inside tissues by exposing it to light of a very specific wavelength, delivered to the tumor site via specially designed fibers placed within the prostate. The procedure achieves excellent outcomes in terms of cancer cure, and may even be a potential therapy for prostate cancers that have spread to the lymph nodes and other organs. VTP is being evaluated in a clinical trial at Memorial Sloan Kettering Cancer Center.